New Indication of CSPC Group 's Butylphthalide Soft Capsules Entered Phase III Trial

BY Caicai

• The Phase III clinical of Butylphthalide Soft Capsules（Trade name: NBP）for the treatment of vascular dementia was officially approved by the Genetics Office in China.
• Butylphthalide is the first internationally innovative drug that acts on multiple pathological links of acute ischemic stroke, and has obtained a number of domestic and international patents.
• In China, only CSPC (Shiyao) has been approved the raw materials and preparations of butylphthalide. In 1999, Shiyao bought the patent of butylphthalide from the Chinese Academy of Medical Sciences for 50 million yuan, which was regarded as a sky-high price. In 2005, butylphthalide soft capsules were approved by the NMPA for marketing. The trade name is NBP (Enbipu) and the specification is 0.1g. It is the first Class 1 new drug in Cardio-cerebrovascular field in China used to treat mild to moderate acute ischemic stroke in patients with stroke; in April 2010, butylphthalide sodium chloride injection was approved for production with a specification of 100ml: 25mg. If you are looking for wholesale medical supply companies who sale NBP, then Pharmasources would be your best choice.
• Enbipu sold 5.6 billion yuan in 19, an increase of 36.6% year-on-year, accounting for 1/4 of the total revenue of CSPC, and it is well-deserved blockbuster medicine. In 2019, butylphthalide soft capsules and injections entered the 2019 New Edition of National Medical Insurance Category B, and sales revenue in 2020 may exceed 6 billion.
• Butylphthalide patent is about to expire. The compound patent expires in 2021, the injection patent expires in 2022, and the capsule patent expires in 2023.